Skip to main content
Journal cover image

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.

Publication ,  Journal Article
Tew, WP; Sill, MW; Walker, JL; Secord, AA; Bonebrake, AJ; Schilder, JM; Stuckey, A; Rice, L; Tewari, KS; Aghajanian, CA
Published in: Gynecol Oncol
November 2018

PURPOSE: Bevacizumab (BV) monotherapy leads to compensatory upregulation of multiple signaling pathways, resulting in mTOR activation. We evaluated combining BV and everolimus (EV), an mTOR kinase inhibitor, to circumvent BV-resistance in women with recurrent or persistent ovarian, fallopian tube or primary peritoneal cancer (OC). PATIENTS AND METHODS: Eligible OC patients had measurable (RECIST1.1) or detectable disease, 1-3 prior regimens, performance status (PS) 0-2, and no prior m-TOR inhibitor. All patients received BV 10 mg/kg IV every 2wks. Patients were randomized (1:1) to oral EV (10 mg daily) or placebo stratified by platinum-free interval (PFI), measurable disease and prior BV. Primary endpoint was progression-free survival (PFS); secondary endpoints included safety and response. RESULTS: 150 patients were randomized to BV with (n = 75) and without (n = 75) EV. Arms were well-balanced for age (median 63: range 28-92), PS (0: 73%, 1-2: 27%), prior regimens (1: 37%, 2: 47%, 3: 16%), prior BV (11%), PFI (<6mos: 65%) and measurable disease (81%). The BV + EV vs BV median PFS was 5.9 vs 4.5 months (hazard ratio [HR] 0.95 (95% CI, 0.66-1.37, p = 0.39)). Median OS was 16.6 vs 17.3 months (HR 1.16 (95% CI, 0.72-1.87, p = 0.55). Objective measurable responses were higher with BV + EV (22% vs 12%). Study removal due to toxicity was higher with BV + EV (29% vs 12%). Toxicity (≥grade 3) from BV + EV were "other GI (mucositis)" (23 vs 1%) and "metabolic/nutrition" (19 vs. 7%); common ≥ grade 2 toxicities with BV + EV were cytopenia, nausea, fatigue and rash. CONCLUSION: The combination regimen (BV + EV) did not significantly reduce the hazard of progression or death relative to BV and was associated with higher rates of adverse events and study discontinuation when compared to BV alone.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

November 2018

Volume

151

Issue

2

Start / End Page

257 / 263

Location

United States

Related Subject Headings

  • Peritoneal Neoplasms
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasms, Glandular and Epithelial
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Humans
  • Female
  • Fallopian Tube Neoplasms
  • Everolimus
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tew, W. P., Sill, M. W., Walker, J. L., Secord, A. A., Bonebrake, A. J., Schilder, J. M., … Aghajanian, C. A. (2018). Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol, 151(2), 257–263. https://doi.org/10.1016/j.ygyno.2018.08.027
Tew, William P., Michael W. Sill, Joan L. Walker, Angeles Alvarez Secord, Albert J. Bonebrake, Jeanne M. Schilder, Ashley Stuckey, Laurel Rice, Krishnansu S. Tewari, and Carol A. Aghajanian. “Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.Gynecol Oncol 151, no. 2 (November 2018): 257–63. https://doi.org/10.1016/j.ygyno.2018.08.027.
Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 Nov;151(2):257–263.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

November 2018

Volume

151

Issue

2

Start / End Page

257 / 263

Location

United States

Related Subject Headings

  • Peritoneal Neoplasms
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasms, Glandular and Epithelial
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Humans
  • Female
  • Fallopian Tube Neoplasms
  • Everolimus